Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BICO Group AB Class B ( (SE:BICO) ) has issued an announcement.
BICO Group AB, a Nasdaq Stockholm Mid-Cap listed provider of lab automation solutions to pharma and biotech, has built a global footprint with tens of thousands of instruments installed in leading laboratories worldwide. Its technologies are widely used in life science research, with thousands of scientific citations underscoring its role in advancing automated lab workflows.
The company announced that it will publish its interim report for the first quarter of 2026 on April 29, 2026, followed by an English-language webcast and teleconference hosted by President and CEO Maria Forss and CFO Ewa Linsäter. By organizing an interactive presentation with Q&A, BICO is seeking to maintain transparent communication with investors and analysts at a time when its automation offerings remain central to productivity and innovation in pharmaceutical and biotech research.
More about BICO Group AB Class B
BICO Group AB is a lab automation partner focused on providing selected workflow solutions to the pharmaceutical and biotech industries. With more than 53,600 instruments installed across over 65 countries and presence in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, its products and software aim to enable and automate the life science lab of the future.
Average Trading Volume: 223,668
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.28B
Find detailed analytics on BICO stock on TipRanks’ Stock Analysis page.